



## FACTSHEET




**Bone Therapeutics** is a leading biotechnology company specializing in the development of cell therapy products for orthopaedics and bone diseases.

Its unique technology allows to produce biologically active bone cells that are able to regenerate a healthy bone environment and promote bone regeneration.

The product candidates have been developed for the treatment of indications with high unmet medical needs such as degenerative diseases of the spine, severe unhealed fractures and osteonecrosis of the hip.


The products, administrable through a minimally invasive percutaneous approach without open surgery, do not require long hospitalization, have already shown encouraging clinical results and address important unmet medical needs.

### Product Pipeline



### Unique Technology Platform

**Bone Therapeutics** is bringing a unique value proposition by developing a range of innovative cell therapy products composed of differentiated bone-forming cells (osteoblasts) that can be administered via a minimally invasive procedure. These differentiated cells offer significant advantages in respect of safety and efficacy compared to undifferentiated stem cells.



### At a glance

- Unique cell therapy products for orthopaedic conditions and bone diseases
- Founded in June 2006
- HQ in Gosselies, Belgium
- Robust pipeline of advanced clinical Phase II and III programs
- Integrated organization with > 100 employees
- Solid IP position
- GMP production facility

### Management

#### Thomas Lienard

Chief Executive Officer  
(Lundbeck, Eli Lilly and Company, McKinsey & Company)

#### Jean-Luc Vandebroek

Chief Financial Officer  
(Alcopa, Fluxys, Ahold Delhaize)

#### Miguel Forte, MD, PhD

Chief Medical Officer  
(ISCT, TxCell, UCB, Nabi Biopharmaceuticals, EMA, Bristol-Myers Squibb, Abbott)

#### Guy Heynen, MD

Chief Clinical & Regulatory Officer  
(Pfizer)

#### Benoit Champluvier, PhD

Chief Technology & Manufacturing Officer  
(GSK)

#### Nora Meskini

Director Clinical Operations  
(Cytori Therapeutics, Biosense Webster)

### Contact

#### Bone Therapeutics SA

Rue Auguste Piccard 37,  
6041 Gosselies

Tel: +32 (0) 2 529 59 90  
Fax: +32 (0) 2 529 59 93

[www.bonetherapeutics.com](http://www.bonetherapeutics.com)

[info@bonetherapeutics.com](mailto:info@bonetherapeutics.com)



## FACTSHEET



### Bone Therapeutics' Products

#### ALLOB®

ALLOB®, Bone Therapeutics' allogeneic osteoblastic (bone-forming) cell product, is derived from cultured bone marrow cells from healthy adult donors. ALLOB® is currently in two Phase II proof-of-concept trials for the treatment of delayed-union fractures and spinal fusion procedures.

#### PREOB®

PREOB®, Bone Therapeutics' autologous osteoblastic cell product, is derived from cultured bone marrow cells from the patient. PREOB® is currently in two pivotal Phase III trials in Europe for osteonecrosis

PREOB® received orphan drug designation for osteonecrosis from the EMA and the FDA.

### Key Financials


(€ million)	H1 2017	H1 2016
<b>Operating income</b>	<b>1.92</b>	<b>1.95</b>
<b>Operating expenses</b>	<b>(8.09)</b>	<b>(7.69)</b>
R&D expenses	(6.43)	(6.01)
G&A expenses	(1.66)	(1.68)
<b>Operating result</b>	<b>(6.16)</b>	<b>(5.74)</b>
<b>Net financial result</b>	<b>(0.20)</b>	<b>(0.13)</b>
<b>Net result</b>	<b>(6.37)</b>	<b>(5.81)</b>
<b>Net cash flow</b>	<b>(7.70)</b>	<b>(7.01)</b>
Operating activities	(6.91)	(6.58)
Investing activities	(0.35)	(0.68)
Financing activities	(0.45)	0.26
<b>Net cash position (at end of period)</b>	<b>12.60</b>	<b>26.60</b>

Cash at the end of June 2017 amounted to EUR 12.60 million. Based on the current strategy, the Company estimates that it will be able to carry out its strategic objectives into Q2-2018, excluding any partnerships or other commercial agreements.

### Investor Facts

- The Company is listed on Euronext Brussels and Euronext Paris with the ticker symbol "BOTHE"
- Bone Therapeutics has 6,849,654 outstanding shares
- Analyst coverage: Hugo Solvet (Bryan, Garnier & Co); Sandra Cauwenberghs, PhD (KBC Securities); Arsene Guekam (Kepler Cheuvreux); Marcel Wijma, MSc (Van Leeuwenhoeck Inc)

### Shareholder Structure



### Board of Directors

#### Steve Swinson

*Chairman*

#### Michel Helbig de Balzac

permanent representative of **Wagram Invest SA**  
*Non-executive Director*

#### Damian Marron

*Independent Director*

#### Dirk Dembski

*Independent Director*

#### Roland Baron

*Independent Director*

#### Chris Buyse

*Independent Director*

#### Paul Magrez

*Independent Director*

#### Thierry François

permanent representative of **Magenta Tree BVBA**  
*Independent Director*

#### Jean-Paul Priels

permanent representative of **SFPI SA**  
*Non-executive Director*

#### Wim Goemaere

*Non-executive Director*

#### Thomas Lienard

*Executive Managing Director*

### A game changer in orthopaedics

- A unique breakthrough technology based on:
  - differentiated bone-forming cells with regenerative capacities and
  - a minimally invasive administration
- Covering a large and diverse portfolio of bone diseases
- To address important unmet medical needs in the field of orthopaedics and bone diseases